We create tailor-made antibodies and assays to quantify unique biomarkers in a wide variety of neurodegenerative diseases and conditions such as Alzheimer’s disease, Parkinson’s disease and traumatic brain injury. Our assays enable early detection before symptoms appear, providing valuable information from the drug development phase up to clinical practice, to improve the life of patients.
Biomarkers increase clinical trial success rate and help bring the right drugs to the right patient. Focus on drug development while we take care of the biomarkers. We build robust and reliable assays tailored to your needs, scaled up by our diagnostic partners and rolled out in time.
We supply antibodies that meet the raw material requirements for IVD test kit manufacturing, and offer continuous support to develop and implement assays into easy-to-use kits for automated platforms, serving both the pharmaceutical companies and the clinic.
ADx bridges the gap between pharma and IVD companies, building partnerships to support innovations that can truly change the life of the patients with neurodegenerative conditions. Our management team combines more than 45 years of experience with an impressive track record developing superior diagnostic biomarkers.
